Scientists combine PSA and drug therapy to create new prostate cancer screening method

9 August 2012

Scientists have developed a new prostate cancer screening method which combines a new drug therapy and gradual changes in prostate specific antigen (PSA) levels to identify individuals who are more likely to have an aggressive form of the disease despite biopsies coming back negative.

According to the paper, published in the Journal of Urology, PSA can be a much more effective market for prostate cancer when a drug therapy is used in conjunction with it. Currently most physicians use it as a standalone test.

Lead investigator Dr Steven A Kaplan explained that the value of PSA is being "increasingly debated," and the research showed that when it is used in a specific way, PSA can be especially useful identifying males with prostate cancer than was previously undetected.

He said: "We have shown that using PSA with these drugs can help us differentiate prostate cancer from benign prostate disease in patients who are difficult to diagnose."

Posted by Edward Bartel

Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.

Find a treatment, test or scan available at:


Find a consultant

Use one or more of the options below to search for a consultant and link through to view their Spire profile.


Let us help you

fill out this form and we will get back to you:

Please select a hospital

We can call you

Please enter your details below and we will call you back.

What is the aim of your enquiry?

Please select a hospital

If we are unable to reach you by phone, please include your email address so that we can get in touch...



© Spire Healthcare Group plc (2016)